Forward Pharma A/S, a biopharmaceutical company, focuses on the provision of dimethyl fumarate (DMF) formulations for the treatment of various immune disorders. It develops FP187, a DMF formulation to treat relapsing remitting multiple sclerosis and psoriasis. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.
Monday, November 3, 2014
Forward Pharma (FWP) began trading on the NASDAQ on 15 October 2014
Forward Pharma A/S, a biopharmaceutical company, focuses on the provision of dimethyl fumarate (DMF) formulations for the treatment of various immune disorders. It develops FP187, a DMF formulation to treat relapsing remitting multiple sclerosis and psoriasis. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.
Labels:
2014 IPOs,
biotech IPOs,
Danish IPOs,
Forward Pharma (FWP)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment